This site is intended for Healthcare Professionals only.

Novo Nordisk invests £1.8 bln in Danish production facility


Share post:

Hot on the heels of its popularity over weight-loss drug Wegovy, Danish drugmaker Novo Nordisk is to invest £1.8 billion to expand a production facility in Denmark for products to treat serious chronic diseases, the company said in a statement on Monday (June 12).

However, the company has clarified that the current expansion is not for the production of semaglutide, the key ingredient in Ozempic and Wegovy, which treat diabetes and weight-loss respectively.

The facility in Bagsvaerd, Denmark produces active pharmaceutical ingredient (API), the main biologically active components of medicines, and will be expanded to produce material for both current and future products.

Novo has faced major supply constraints of semaglutide after it was overwhelmed by massive demand for Wegovy during its launch in the United States in 2021, and has invested heavily to increase the supply.

Last month, the firm said it would ration the supply of starter doses for Wegovy in the U.S. to cope with demand.

Construction of the new facility is underway and it is expected to start producing API by early 2029.

“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” Novo’s head of product supply, quality and IT, Henrik Wulff, said in a statement.


Please enter your comment!
Please enter your name here

Current Issue December 2023

Related articles

NPA raises question of accountability over authorising of pharmacy technicians

The government’s formal consultation on pharmacy supervision, which closes today (29 February), leaves important questions unanswered, the National...

Britain seeks ‘urgent reversal’ of fall in childhood vaccination rates

The government will on Thursday launch a drive to boost childhood vaccination rates, health authorities said, seeking an...

Health and care worker visas almost doubled in 2023

Britain almost doubled the number of visas awarded to foreign migrants coming to work in the health and...

Pfizer says its RSV shot is protective through a second year

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its...